NCT02988960 2026-01-09A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsAbbViePhase 1 Active not recruiting163 enrolled
NCT05599984 2025-10-20Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid TumorsAbbViePhase 1 Active not recruiting288 enrolled
NCT03893955 2025-08-12A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsAbbViePhase 1 Active not recruiting150 enrolled
NCT03821935 2025-05-25Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsAbbViePhase 1 Active not recruiting364 enrolled
NCT06119217 2024-12-04Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC PatientsTrishula Therapeutics, Inc.Phase 2 Active not recruiting194 enrolled